FDA advisers back Pfizer’s COVID-19 vaccine for young kids

Date:

By LAURAN NEERGAARD and MATTHEW PERRONE Associated Press

WASHINGTON (AP) — A panel of U.S. health advisers on Tuesday endorsed kid-size doses of Pfizer’s COVID-19 vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11.

A Food and Drug Administration advisory panel voted unanimously with one abstention that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks — including a heart-related side effect that’s been very rare in teens and young adults who get a much higher dose.

The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision within days.

If the FDA authorizes the kid-size doses, there’s still another step: Next week, the Centers for Disease Control and Prevention will have to decide whether to recommend the shots and which youngsters should get them.

While children are at lower risk of severe COVID-19 than older people, 5- to 11-year-olds still have faced substantial illness — including over 8,300 hospitalizations reported, about a third requiring intensive care, and nearly 100 deaths.

The dose for young children is just one-third of the Pfizer shot already recommended for everyone 12 and older. Moderna also is studying its vaccine for young children.

THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.

WASHINGTON (AP) — Kid-size doses of Pfizer’s COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating whether there’s enough evidence that the shots are safe and effective for 5- to 11-year-olds.

A study of elementary schoolchildren found the Pfizer shots are nearly 91% effective at preventing symptomatic infection — even though the youngsters received just a third of the dose given to teens and adults.

In a preliminary analysis last week, Food and Drug Administration reviewers said that protection would “clearly outweigh” the risk of a very rare side effect in almost all scenarios of the pandemic. Now FDA’s advisers are combing through that data to see if they agree.

If the FDA authorizes the kid-size doses, there’s still another step: Next week, the Centers for Disease Control and Prevention will have to decide whether to recommend the shots and which youngsters should get them.

While children are at lower risk of severe COVID-19 than older people, 5- to 11-year-olds still have faced substantial illness — including over 8,300 hospitalizations, about a third requiring intensive care, and nearly 100 deaths, FDA vaccine chief Dr. Peter Marks told the advisory panel.

Also, “infections have caused many school closures and disrupted the education and socialization of children,” he said.

“I want to acknowledge the fact that there are strong feelings” among the public for and against child vaccinations, Marks added, noting that the discussion would be on scientific data “not about vaccine mandates, which are left to other entities outside of FDA.”

Full-strength shots made by Pfizer and its partner BioNTech already are recommended for everyone 12 and older but pediatricians and many parents are clamoring for protection for younger children. The extra-contagious delta variant has caused an alarming rise in pediatric infections — and families are frustrated with school quarantines and having to say no to sleepovers and other rites of childhood to keep the virus at bay.

States are getting ready to roll out shots for little arms — in special orange-capped vials to distinguish them from adult vaccine — as soon as the government gives the OK. More than 25,000 pediatricians and other primary care providers have signed up so far to offer vaccination.

Pfizer’s study tracked 2,268 children ages 5 to 11 who got two shots three weeks apart of either a placebo or the kid dose. Vaccinated youngsters developed levels of virus-fighting antibodies just as strong as teens and young adults who got the full-strength shots.

And so far, 16 kids given dummy shots developed symptomatic COVID-19 compared to three vaccinated youngsters, meaning the vaccine was nearly 91% effective. Most of the study data was collected in the U.S. during August and September as the delta variant surged.

The kid dosage also proved safe, with similar or fewer temporary side effects — such as sore arms, fever or achiness — that teens experience. At FDA’s request, Pfizer more recently enrolled another 2,300 youngsters into the study, and preliminary safety data has shown no red flags.

The study isn’t large enough to detect any extremely rare side effects, such as the heart inflammation that occasionally occurs after the second dose, mostly in young men and teen boys.

The FDA’s panel of independent experts will weigh whether Pfizer’s shot is likely to prevent more COVID-19 hospitalizations in young kids than might be caused by that rare side effect.

The FDA analysis calculated that in most scenarios of the continuing pandemic, the vaccine would prevent roughly 200 to 250 COVID-19 hospitalizations for every 1 million youngsters vaccinated, with about 58 hospitalizations for the heart inflammation. The side effect risk is based on levels in teens, and Pfizer expects it to be far lower in youngsters getting the kid-size dose.

Moderna also is studying its vaccine in young children.

Find your latest news here at the Hemet & San Jacinto Chronicle

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe to The Hemet & San Jacinto Chronicle

Popular

More like this
Related

Student Talent Takes Center Stage at San Bernardino County Honor Concerts

More than 650 student musicians from throughout San Bernardino County were selected to showcase their musical talents during three separate honor concerts

Writers Corner: Motivation

Brad from Rancho Cucamonga asks me to explain motivation. That may appear to be a dumb question, but it isn't. I've been asked that question a number of times.

$783K Awarded to Support Urban Agriculture and Farmers via Inland Empire Resource Conservation District

This week, the California Department of Food and Agriculture’s Office of Farm to Fork announced $11.67 million in funding awards through their Urban Agriculture Program focused on urban and disadvantaged communities throughout the state.

Clergy Corner: Better Than $150,000.00?

 The Boston Marathon! What an amazing race! Back when I was in high school and spending a fair amount of time running track, my dad told me if I would prepare for the Boston Marathon and meet the qualifying time, he would sponsor me.